Recently, interleukin (IL)-9 was found to be involved in the pathogenesis of many inflammatory diseases. Here, we tested whether IL-9 was related to atherosclerosis and investigated the underlying mechanisms.
Introduction
Atherosclerosis is a multifactorial disease that is characterized by chronic inflammation of the arterial wall. 1 Both innate and adaptive immune responses play vital roles in the process of atherosclerosis, as reflected by the large number of inflammatory cells within atherosclerotic plaques, including mainly monocyte-derived macrophages and T-lymphocytes. 1, 2 The inflammatory cells that invade lesions produce large amounts of soluble inflammatory cytokines and chemokines, which are critically important in the initiation and development of the disease. 1,2 Secreted pro-inflammatory cytokines such as interferon-gamma (IFN-g), tumour necrosis factor-alpha (TNF-a), interleukin (IL)-1, IL-12, IL-18, 3 and many chemokines have pro-atherosclerotic effects, while some anti-inflammatory cytokines such as IL-10 3 and IL-33 4, 5 have anti-atherosclerotic effects during all stages of atherosclerosis. IL-9 was first described as a T cell and mast cell growth factor and has pleiotropic functions in the immune system. 6 Multiple cell types, including T cells, mast cells, and natural killer T cells (NKTs), produce IL-9. 6 IL-9
acts on a variety of cells through the IL-9 receptor (IL-9R), which is composed of IL-9Ra and the common g chain shared by IL-2, IL-4, and IL-7.
7,8
The binding of IL-9 to IL-9R mainly activates JAK1 and JAK3, which leads to the downstream activation of signal transducer and activator of transcription (STAT) 1, 3, and 5. 9, 10 Accumulated evidence has demonstrated that IL-9 plays an important role in the regulation of inflammatory responses. It has been reported that IL-9 is related to the pathogenesis of allergic inflammation, 11, 12 intestinal parasites, 13, 14 infectious diseases, 15, 16 cancer immunity, 17, 18 and autoimmune inflammatory disorders such as experimental autoimmune encephalomyelitis (EAE). 19 -21 Recently, IL-9 was also found to be increased in plasma and carotid plaques in patients with carotid and coronary atherosclerosis. 22 However, the role of IL-9 in atherosclerosis remains largely unclear. In this study, we investigated whether IL-9 was involved in the progression of atherosclerosis and further explored the associated mechanisms. We demonstrated that IL-9 aggravated the development of atherosclerosis in ApoE2/2 mice partially through induction of VCAM-1 expression and inflammatory cell infiltration.
Methods
Expanded Methods descriptions are available in the Supplementary material online.
Mice and treatment groups
Male C57BL/6 and ApoE2/2 mice aged 6-8 weeks weighing 20 -25 g were purchased from Beijing University (Beijing, China). The mice were maintained in a specific pathogen-free facility on a 12 h light:12 h dark cycle at 258C. C57BL/6 and ApoE2/2 mice were fed a chow diet or high-fat diet (western type diet, containing 0.15% cholesterol, 21% fat). All animals were cared for in accordance with the NIH guidelines and all animal studies were supported by the Animal Care and Utilization Committee of Huazhong University of Science and Technology. The detailed treatment groups are provided in the Supplementary material online, Methods.
Patient selection and sample collection
The clinical investigation was performed based on the standards of the Declaration of Helsinki. The experiment was supported by the Ethics Committee of Tongji Medical College of Huazhong University of Science and Technology, and all the selected patients provided written informed consent. The experiment protocols are provided in the Supplementary material online, Methods.
Results

IL-9R is expressed in endothelial cells and aortic tissues
IL-9R is widely expressed in T cells, mast cells, airway smooth muscle cells, epithelial cells, and other cell types. 23 Recently, IL-9R was also found in human carotid plaques. 22 However, the expression of IL-9R
in endothelial cells and murine aortic tissues has not been previously reported. We investigated the expression of IL-9R in endothelial cells and murine aortic tissues using real-time PCR and western blotting. For detecting the expression of IL-9R in mouse aortic endothelial cells (MAECs), splenocytes were used as a positive control. The results showed that IL-9R was present in MAECs (Supplementary material online, Figure S1A ). Meanwhile, IL-9R was expressed in the aortic tissues of C57BL/6 control mice (18 weeks, fed a chow diet or western diet) and ApoE2/2 mice (18 weeks, fed a chow diet or western diet), and its expression was similar among the groups independent of atherosclerotic lesions (Supplementary material online, Figure S1B and C). In addition, we determined the expression of IL-9R in the early plaque (western diet for 6 weeks) and advanced plaque (western diet for 24 weeks), and different sites (abdominal aorta and thoracic aorta including the aortic arch) in ApoE2/2 mice (western diet for 10 weeks) by RT-PCR and western blotting. The result showed that there was also no significant difference in IL-9R expression among the groups (Supplementary material online, Figure S2 ).
IL-9 is increased in ApoE2/2 mice
Next, to examine the involvement of IL-9 in atherosclerosis, we investigated IL-9 levels and mRNA expression in the plasma and aortic arches. We found that IL-9 levels in the plasma of ApoE2/2 mice were obviously increased compared with those in C57BL/6 mice (western diet for 10 weeks) (314.41 + 32.19 pg/mL vs. 150.56 + 18.11 pg/mL, P , 0.01) ( Figure 1A ). At the same time, IL-9 mRNA expression in ApoE2/2 mice (western diet for 10 weeks) in aortic arches was Figure 1 IL-9 is increased in ApoE2/2 mice. IL-9 levels in the plasma and mRNA expression in aortic arches were assessed by Bio-Plex system and real-time PCR. (A) The concentration of IL-9 was detected by Bio-Plex system in C57BL/6 and ApoE2/2 mice fed a chow diet or western diet for 10 weeks (n ¼ 8). *P , 0.05 and **P , 0.01. (B) IL-9 mRNA expression in aortic arches in C57BL/6 and ApoE2/2 mice fed a chow diet or western diet for 10 weeks was determined by real-time PCR (n ¼ 6). **P , 0.01. (C) IL-9 mRNA expression in aortic arches in early plaque (ApoE2/2 mice fed a western diet for 6 weeks) and advanced plaque (ApoE2/2 mice fed a western diet for 24 weeks) was determined by real-time PCR (n ¼ 6).
almost three-fold higher than those in C57 mice (western diet for 10 weeks) ( Figure 1B) , while RT-PCR demonstrated a similar pattern of IL-9 expression in early plaque and advanced plaque ( Figure 1C) . Multiple cell types, including T cells, and innate immune cells, could produce IL-9. 6 To determine which leucocytes account for the increase of IL-9 in ApoE2/2 mice fed a western diet, we performed intracellular cytokine staining combined with staining for some surface markers. Figure   S3 ), indicating that innate immune cells mainly account for the production of IL-9 during atherosclerosis.
Neutralization of endogenous IL-9 protects against atherosclerosis development
Then, to determine the impact of IL-9 in atherosclerosis, the anti-IL-9 neutralizing mAb was used to block endogenous IL-9 in ApoE2/2 mice (6-8 weeks, fed a western diet containing 0.15% cholesterol and 21% fat). The results showed that the aortic plaque burden was significantly smaller in mice treated with IL-9 mAb (3.68 + 0.51%) compared with the isotype control group (6.46 + 0.94%) or PBS group (6.31 + 0.88%) (P , 0.05) (Figure 2A and B Figure 2C and D) . At the same time, IL-9 mAb treatment significantly decreased the areas of Mac-3 + macrophage ( Figure 2G and H ) and CD3 + T cell ( Figure 2E and F ) infiltration in plaques compared with the isotype control group or PBS group. In addition, treatment with IL-9 mAb did not affect body weight, plasma total cholesterol, triglycerides, or high-density lipoprotein cholesterol (HDL-C) ( Table 1) .
Treatment with rIL-9 exacerbates atherosclerosis development
Then, to further demonstrate the role of IL-9 in the development of atherosclerosis, we treated the ApoE2/2 mice (6-8 weeks, fed a western diet containing 0.15% cholesterol and 21% fat) with recombinant IL-9 for 10 weeks. Administration of rIL-9 led to a significant elevation of circulating IL9 levels in plasma compared with PBS group (629.40 + 105.53 pg/mL vs. 310.30 + 34.93 pg/mL, P , 0.01) (Supplementary material online, Figure S4 ), while we found no change in the number of mast cells in the adventitia in mice treated with rIL9, suggesting that at this dosage and time, IL-9 did not promote mast cell proliferation and activation (Supplementary material online, Figure S5 ). In addition, treatment with rIL-9 did not affect body weight, plasma total cholesterol, triglycerides, or high-density lipoprotein cholesterol (HDL-C) ( Table 2 ). The lesion area was first determined in aortas pinned out en face. The aortic plaque burden was significantly greater in mice treated with rIL-9 compared with the PBS-treated group (10.62 + 1.29% vs. 5.76 + 0.74%, P , 0.01) ( Figure 3A and B) . Meanwhile, the plaque size in the aortic root was analysed. The atherosclerotic lesion area was obviously increased in mice treated with rIL-9 compared with the PBS-treated group (520.94 + 41.54 × 10 3 mm 2 vs. 363.96 + 30.97 × 10 3 mm 2 , P , 0.01) ( Figure 3C and D). Simultaneously, rIL-9 treatment significantly increased the areas of Mac-3 + macrophage and CD3 + T cell infiltration in plaques ( Figure 3E and F ). In addition, on better characterization of the lesions, we performed SM-22a, Masson, Sirius red, HaematoxylinEosin (H&E), and TUNEL stainings of lesions, and found no significant difference in the content of smooth muscle cells (SMC), collagen, necrotic cores, and apoptotic cells between the two groups ( Figure 2E and F and Supplementary material online, Figure S6 ), indicating that IL-9 increased plaque size independent of them.
Treatment with rIL-9 does not alter T cell or monocyte subset profiles
To explore the immunological profile of mice treated with rIL-9, splenic T cell and periphery monocyte subsets were investigated by flow cytometry. Flow cytometric analysis of splenic cells showed that treatment with rIL-9 did not affect T cell subsets, including Th1, Th2, Th17, and T regulatory cells (Tregs) (Supplementary material online, Figure S7 ). At the same time, the concentration of IFN-g, IL-4, IL-17A, and IL-10 in the culture supernatants and plasma were also not altered in mice treated with rIL-9 (Supplementary material online, Figure S8 ). In addition, treatment with rIL-9 did not affect the percentage of CD11b + Ly6G 2
Ly6C
+ monocytes or Ly6C high and Ly6C low monocyte subsets in the peripheral blood of mice (Supplementary material online, Figure S9 ). It has been reported that IL-9 can enhance the suppressive functions of Tregs and consequently alleviate inflammatory responses. 19 However, in our study, we found no significant difference in the suppressive functions of Tregs after rIL-9 treatment (Supplementary material online, Figure S10 ).
IL-9 increases VCAM-1 expression in vivo
It is known that VCAM-1 plays an important role in initiation and progression of atherosclerosis. 24, 25 Interestingly, in our study, we found that the VCAM-1-positive area in plaques and the proportion of VCAM-1 + endothelial cells in the total endothelial cell populations were obviously increased in mice treated with rIL-9 relative to the PBS-treated group, and decreased in mice treated with IL-9 mAb compared with the isotype control group or PBS group ( Figure 4A -C ). Meanwhile, VCAM-1 mRNA expression in the aortic arches of mice treated with rIL-9 was markedly higher, while VCAM-1 mRNA expression in the aortic arches of mice treated with IL-9 mAb was significantly lower ( Figure 4D ). In addition, the concentration of sVCAM-1 in the plasma of mice treated with rIL-9 was obviously increased compared with that in the PBS-treated group, whereas the concentration of sVCAM-1 in the plasma of mice treated with IL-9 mAb was obviously decreased compared with the isotype group or PBS group ( Figure 4E ).
IL-9 induces VCAM-1 expression in murine aortic endothelial cells mainly via a STAT3-dependent pathway
Having demonstrated that IL-9 induces VCAM-1 expression in vivo, we next investigated whether IL-9 could induce VCAM-1 expression in MAECs in vitro. To determine the effect of IL-9 on VCAM-1 expression, MAECs were first treated with different concentration of rIL-9 for 12 h, and we found that the mRNA expression of VCAM-1 was in a concentration-dependent manner and the optimum concentration of IL-9-induced MAECs VCAM-1 expression was 100 ng/mL ( Figure 5A ). Then, we treated MAECs with rIL-9 (100 ng/mL) for different periods of time, and found that VCAM-1 mRNA expression increased as early as 3 h after rIL-9 treatment, rose to a peak at 12 h, and subsequently began to decrease ( Figure 5B) , and the protein expression of VCAM-1 obviously increased at 6 h and reached a peak at 24 h ( Figure 5C ).
To confirm the increased VCAM-1 expression in MAECs after IL-9 stimulation, the adhesion of monocytes to endothelial cells was evaluated. Monocytes labelled with CFSE were added to the MAECs after treatment with rIL-9 for 24 h. Treatment with rIL-9 significantly increased monocyte -endothelial adhesion compared with the control, while neutralization of VCAM-1 using anti-VCAM-1 antibody completely abrogated rIL-9-induced monocyte -endothelial adhesion, indicating that VCAM-1 played an important role in rIL-9-mediated monocyte -endothelial adhesion ( Figure 5D and E). Next, we studied the downstream events related to stimulus -receptor coupling. Cells were treated with rIL-9 (100 ng/mL) for 0, 5, 10, 20, or 30 min, and phosphorylated STAT1, 3, and 5 were detected using western blotting. IL-9 did not induce phosphorylation of STAT1 or 5 (Supplementary material online, Figure S11A) ; however, it induced rapid STAT3 phosphorylation within 10 min that disappeared afterwards (Supplementary material online, Figure S11A ). To confirm that STAT3 phosphorylation is involved in the VCAM-1 up-regulation induced by IL-9, the specific inhibitor S3I201 and a siRNA directed against STAT3 were used to inhibit STAT3 phosphorylation and disrupt total STAT3 expression, respectively. We found that pretreatment with the STAT3 specific inhibitor S3I201 (100 mM and 200 mM) for 2 h resulted in significantly decreased STAT3 phosphorylation (Supplementary material online, Figure S11B ) and IL-9-mediated VCAM-1 expression (Supplementary material online, Figure S11C ) in MAECs. At the same time, transfection of MAECs with STAT3 siRNA for 48 h significantly decreased total STAT3 expression (Supplementary material online, Figure S11D ) and thus markedly reduced IL-9-induced VCAM-1 expression (Supplementary material online, Figure S11E ), suggesting that IL-9 induces VCAM-1 expression in MAECs mainly via the activation of STAT3.
Neutralization of VCAM-1 prevents the IL-9-induced increase in plaque size
The above results demonstrated that rIL-9 can induce VCAM-1 expression in vivo and in vitro. Furthermore, VCAM-1 plays an important role in atherosclerosis. 24, 25 Thus, to determine whether VCAM-1 is directly related to the increase in plaque formation after rIL-9 treatment, we conducted a VCAM-1 neutralization study. Mice that were treated with rIL-9 and an isotype control antibody showed a significant increase in plaque area in both the aorta and aortic root relative to the isotype group (10.52 + , P , 0.01, respectively) ( Figure 6A -D) . Furthermore, mice treated with rIL-9 that received anti-VCAM-1 neutralizing antibody revealed an obvious decrease in plaque area in both the aorta and aortic root relative to rIL-9 and isotype-matched antibody group (6. indicating that VCAM-1 is directly involved in the pro-atherogenic effects of IL-9, but neutralization of VCAM-1 did not completely reverse the increase in plaque size caused by IL-9 ( Figure 6A -D) . Meanwhile, mice that were treated with rIL-9 and isotype control antibody showed a marked increase in the area of Mac-3 + macrophages and CD3 + T cell infiltration in plaques compared with isotype antibodytreated mice, while mice treated with rIL-9 and anti-VCAM-1 neutralizing antibody showed a significant decrease in the area of Mac-3 + macrophages and CD3 + T cell infiltration in plaques compared with mice treated with rIL-9 and isotype antibody (Supplementary material online, Figure S12 ). Moreover, inflammatory cell infiltration including CD3 + T cell and macrophages in plaques in rIL-9 and anti-VCAM-1 neutralizing antibody group were obviously increased compared with only anti-VCAM-1 mAb group (Supplementary material online, Figure S12 ). In addition, the treatment did not alter body weight, plasma total cholesterol, triglycerides, or high-density lipoprotein cholesterol (HDL-C) ( Table 3) .
CD4
1 IL-9 1 T cells and IL-9 are increased in patients with acute coronary syndrome
Having revealed the role of IL-9 in atherosclerosis in ApoE2/2 mice, we next determined whether IL-9 is involved in atherosclerosis in humans. We detected the percentages of CD4
+ IL-9 + T cells and the concentration of IL-9 in culture supernatants in 66 acute coronary syndrome (ACS) patients, 37 chronic stable angina (CSA) patients, and 55 chest pain syndrome (CPS) patients by flow cytometry and ELISA. The basic clinical characteristics of the enrolled patients are shown in Table 4 . The percentage of CD4 + IL-9 + T cells within the CD4 + T cell populations was significantly higher in the patients with ACS (0.70 + 0.037%) than in those with CSA (0.41 + 0.029%) or CPS (0.36 + 0.023%) (P , 0.001), whereas there was no obvious difference between the CSA and CPS groups (P . 0.05) ( Figure 7A and B) . Moreover, the absolute number of peripheral CD4 + IL-9 + T cells was also significantly higher The role of IL-9 in atherosclerosis material online, Table S1 ). The levels of IL-9 in the culture supernatants was also obviously higher in patients with ACS (77.01 + 10.72 pg/mL) (P , 0.001) than in those with CSA (37.61 + 5.65 pg/mL) and CPS (32.05 + 3.84 pg/mL) ( Figure 7C ).
As we have shown in Table 4 , the study population in the three groups were different in their use of aspirin, clopidogrel, b-blockers, statins, ACE-I or ARBs, or nitrates, incidence of current smoking. To adjust the data on IL-9 or CD4 + IL-9 + T cells for above these variables, we performed a multiple linear regression analysis, and found that the use of medication and current smoking status did not influence IL-9 or CD4 + IL-9 + T cells (Supplementary material online, Table S2 ).
We have demonstrated that IL-9 can increase VCAM-1 expression in ApoE2/2 mice. However, the relationship between IL-9 and VCAM-1 in humans was not previously determined. In this study, the concentration of sVCAM-1 was determined in the plasma of patients in whom IL-9 was also determined. The concentration of sVCAM-1 was significantly higher in ACS patients (654.49 + 32.74 ng/mL) (P , 0.001) than in those with CSA (560.62 + 31.33 ng/mL) or CPS (456.86 + 17.43 ng/ mL), while there was also significant difference between the CSA and CPS groups (P , 0.05) ( Figure 7D ). Spearman's correlation test demonstrated a moderate positive correlation between IL-9 and sVCAM-1 in the enrolled patients (r ¼ 0.401, P , 0.001) ( Figure 7E ). 
Discussion
The current study demonstrates a key role for IL-9 in mediating atherosclerotic plaque formation in ApoE2/2 mice. The data revealed that IL-9R was expressed in MAECs and aortic tissues, and IL-9 was increased in plasma and aortic arches in ApoE2/2 mice. Treatment with rIL-9 markedly increased the plaque area, which was related to an increase in VCAM-1 expression and infiltration of macrophages and T cells. Treatment with anti-IL-9 mAb induced the opposite effect. In vitro studies revealed that treatment with rIL-9 could induce VCAM-1 expression mainly via a STAT3-dependent pathway in MAECs, subsequently increasing monocytes adhesion of endothelial cells. Furthermore, the VCAM-1 neutralization study confirmed that IL-9 aggravated atherosclerotic plaque formation partially via increased VCAM-1 expression. In addition, we also found that IL-9 and CD4 + IL-9 + T cells were obviously increased in patients with acute coronary syndrome, and the concentrations of IL-9 in culture supernatants and sVCAM-1 in plasma showed a moderate positive correlation in the enrolled patients. Recently, emerging evidence has indicated that IL-9 has a role in regulating immune responses and is involved in the pathogenesis of various The role of IL-9 in atherosclerosis inflammatory diseases. 6 However, little is known about the role of IL-9 in the development of atherosclerosis. Our data, for the first time, showed that IL-9R was expressed in MAECs and aortic tissues. Moreover, we found that the levels of IL-9 in the plasma and aortic arches were significantly higher in atherosclerotic mice, especially those fed a western type diet. These data suggested that IL-9 might affect the development of atherosclerosis by interacting with IL-9R. We investigated the cellular source of IL-9 in ApoE2/2 mice. As suggested by previous study, the main cellular sources of IL-9 are T cell subsets, especially Th2 cells, Th17 cells, Treg cells, and a recently identified Th9 cells. 6, 23 However, we found that innate immune cells other than T or B cells were the main source of IL-9 in ApoE2/2 mice. There have also been reported that innate immune cells including mast cells and NKTs, could produce IL-9. 6 Recently, using IL-9 fate reporter mice, it is reported that IL-9 production in vivo was mainly stemmed from innate lymphoid cells (ILCs), and rapidly lost in papain-induced lung inflammation. 26 To study the effect of IL-9 directly, we treated ApoE2/2 mice with exogenous rIL-9 and anti-IL-9 mAb for 10 weeks. We discovered that administration of rIL-9 markedly increased plaque size, as accompanied by increased macrophage and T cell infiltration, whereas administration of anti-IL-9 mAb obviously reduced plaque size, indicating a key role for IL-9 in atherosclerotic plaque formation. The mechanisms of IL-9 effects in atherosclerosis are further studied. The downstream effect of IL-9 has been primarily associated with mast cells that acts as a growth factor of mast cells and increase the activity.
6,27 However, we found that both the number and activity of mast cells in the atherosclerotic plaque were not altered by IL-9, indicating that IL-9 aggravated the progression of atherosclerosis independent of mast cell activation and expansion. There are also some indications that IL-9 exerts its effects by targeting the T cell subsets. In the EAE model, IL-9 could induce Th17 differentiation and enhance the suppressive functions of Treg cells. 19, 20 In vitro experiments demonstrated that IL-9 together with TGF-b1 can cause naïve CD4 + T cells to differentiate into Th17 cells. 19, 28 However, in ApoE2/2 mice, we found that treatment with rIL-9 did not affect the number of T-cell subsets including Th1, Th2, Th17, and Treg cells and their capacity to secret cytokines or suppress proliferation. This discrepancy may be a result of the pleiotropic functions of IL-9, the differences in the disease models or the dependence of T-cell subsets differentiation on the cytokines milieu of the microenvironment rather than a single cytokine.
Many studies have demonstrated that monocytes have an active role in atherosclerosis. Monocytes circulating in the blood can infiltrate into the plaque, where they could become macrophages, release proinflammatory cytokines, and accelerate atherosclerotic plaque formation. 1 The role of IL-9 in atherosclerosis to macrophages in atheromata in ApoE2/2 mice. 31 Therefore, monocytes and their subsets were investigated in our study. The results demonstrated that the percentages of monocytes and their subsets were not altered after rIL-9 treatment. VCAM-1 is an immunoglobulin superfamily member that mediates leucocyte adhesion. The high level of VCAM-1 expression on the membrane of endothelial cells is an important marker of endothelial activation. 32 Moreover, endothelial activation is considered the most important step in the initiation of atherosclerosis. Our data revealed that IL-9 could promote VCAM-1 expression in ApoE2/2 mice, which might cause macrophage and T-cell infiltration and aggravate the development of atherosclerosis. Our in vitro experiments further confirmed that IL-9 could induce VCAM-1 expression in MAECs, consequently leading to a significant increase in monocyte-endothelial adhesion. The combination of IL-9 with IL-9R mainly results in the activation of signal transducer and activator of transcription (STAT) 1, 3, and 5. 33 In the present study, we found that IL-9 did not activate STAT1 or 5 but induced STAT3 phosphorylation in MAECs. Moreover, disruption of STAT3 activity with the specific inhibitor S3I201 or STAT3 siRNA nearly abolished IL-9-induced VCAM-1 expression. These data indicated that STAT3 activation is critical for IL-9-mediated VCAM-1 expression in MAECs, which may contribute to arterial inflammation. VCAM-1 has been demonstrated to play a key role in the infiltration of monocytes and other leucocytes into atherosclerotic plaques. 24, 25 Blockade of VCAM-1 with a VCAM-1 neutralizing antibody or disruption of the fourth Ig domain of VCAM-1 resulted in reduced monocyte adhesion and atherosclerotic lesion formation. 25, 34, 35 In this study, we found that co-administration of rIL-9 and anti-VCAM-1 mAb showed significant increase in plaque area compared with mice treated with only anti-VCAM-1 mAb group, indicating that in addition to increased VCAM-1 expression and consequent inflammatory cell infiltration, there are other mechanisms underlying the pro-atherogenic effects of IL-9 in ApoE2/2 mice that must be further investigated. As a result, in the present study, we hypothesized that IL-9 significantly increased the plaque area in ApoE2/2 mice at least partially through increased VCAM-1 expression, which caused macrophage and T-cell infiltration into the plaques. Thus far, a number of studies in humans have demonstrated that IL-9 and Th9 cells are associated with allergy diseases 36 and anti-tumour immunity. 17 Our study demonstrated that the concentration of IL-9 in culture supernatants and the percentage of CD4 + IL-9 + T cells were increased in patients with acute coronary syndrome. Simultaneously, the concentration of sVCAM-1 in plasma was also obviously increased in patients with coronary heart diseases (CAD). The concentrations of sVCAM-1 have been consistently shown to be a strong independent predictor of future fatal cardiovascular event in patients with established CAD. 37 In consistent with animal experiments, we found that IL-9 and sVCAM-1 had a moderate positive correlation in the enrolled patients. However, additional details regarding the roles of IL-9 and CD4 + IL-9 + T cells in inflammatory atherosclerotic diseases in humans need to be further investigated. Based on our study that IL-9 could exacerbate atherosclerosis development in mice and increased in patients with ACS, targeting IL-9 pathway may provide a new therapeutic strategy for coronary artery disease. Recently, MEDI-528, a monoclonal antibody targeting IL-9, has been shown to alleviate mild-to-moderate asthma without major safety concerns. 38 Therefore, further studies are needed to determine the therapeutic potential of MEDI-528 for the treatment of coronary artery disease. Our study has some limitations. First, we conclude the results by administering exogenous rIL-9 or anti-IL-9 neutralizing mAb, the results should be confirmed by using IL-9 transgenic or IL-9/IL-9R knockout mice. Secondly, the role of IL-9 in advanced plaques and plaque instability has not been addressed in this study. At last, the mechanisms underlying the pro-atherosclerotic effects of IL-9 have not completely illuminated, and other mechanisms in addition to increased VCAM-1 expression should be further investigated.
In summary, our study is the first to demonstrate that IL-9 aggravates the progression of atherosclerosis at least partially by inducing VCAM-1 expression, which mediates the infiltration of lesion-associated macrophages and T cells into atherosclerotic lesions. The role of IL-9 in atherosclerosis that control of IL-9 might be beneficial for controlling the inflammation associated with atherosclerosis.
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